A new test for rapid large-scale testing of COVID-19

A new test for rapid large-scale testing of COVID-19

OU Medicine, the OU Health Sciences Center and the Oklahoma Medical Research Foundation collaborated to create a new test for COVID-19 using technology and reagents from Fluidigm Corporation, an innovative biotechnology tools provider. The test is intended for large-scale testing of patients across the OU Medicine healthcare system, with the capacity to test 180,000 samples over the next 90 days. High-complexity laboratories like OU Medicine's that are certified by CLIA (Clinical Laboratory Improvement Amendments) are eligible to create their own diagnostic test for COVID-19, according to new guidance issued by the U.S. Food and Drug Administration. OU Medicine has applied for Emergency Use Authorization for the test from the FDA. We are grateful for the collaboration and leadership of the researchers at OU Health Sciences Center and OMRF. This partnership with three Oklahoma healthcare leaders and Fluidigm makes it possible for OU Medicine to offer this unique testing capability to our stateWe believe this greatly increased number of tests will serve as a turning point in our battle against the COVID-19 pandemic." Chuck Spicer, FACHE, President and CEO of OU Medicine, Inc. "Readily accessible and rapid testing for COVID-19 not only expedites treatment for patients who test positive, but it allows healthcare providers to be routinely tested to ensure their safety and that of everyone they encounter," Spicer added. "Increased testing will also allow more patients without COVID-19 to access specialty care at OU Medicine, including surgeries, procedures and other diagnostic testing." The testing platform will produce results quickly - in about six hours - which will allow physicians to promptly begin treatment on patients who test positive, and will help public health officials gain a more accurate picture of the spread of the virus in Oklahoma. OMRF's experience with Fluidigm's microfluidics technology and its Fluidigm Biomark™ HD system was a crucial component in the creation and validation of the test. The FAA Civil Aerospace Medical Institute in Oklahoma City also provided a Biomark™ HD system for use in the testing. Microfluidics technology generates more data and uses a fraction of limited testing reagents per sample compared with more traditional technology. Solutions that offer scale and high-speed processing are critically important in ramping up testing capabilities for COVID-19,We anticipate that the test will generate several thousand test results per day, and it comes online at a particularly critical time for COVID-19 patients in Oklahoma." Stephen Prescott, M.D., OMRF President Rapid, high-capacity testing will continue to be critical for contact tracing - determining how many people have been exposed to an infected person. Testing will remain fully functional for as long as patients and the residents of Oklahoma need to be tested. That capability will help the state determine when and how Oklahomans can begin returning to work and their daily lives following the peak of the pandemic. The remarkable volume of testing made available through the tireless work of our OU Health Sciences Center researchers and partners at OU Medicine, OMRF, and Fluidigm is, simply put, game-changing," said OU Interim President Joseph Harroz Jr. "As this innovative testing platform ramps into full capacity, we will be able to ensure Oklahoma has consistent testing for the current environment and for possible future outbreaks, as well as demographic and geographic sampling that can help contain further spread." Joseph Harroz Jr., OU Interim President Related Stories



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More